title: Usefulness of bezafibrate for ovulation induction in clomiphene citrate-resistant polycystic ovary syndrome patients with dyslipidemia: a prospective pilot study of seven cases.
abstract: BACKGROUND
  Dyslipidemia is commonly observed in polycystic ovary syndrome (PCOS) patients. Bezafibrate is a drug for dyslipidemia acting through peroxisome proliferator-activated receptors. We investigated the effects of bezafibrate for ovulation induction in patients with PCOS with dyslipidemia who were resistant to clomiphene citrate (CC).
  
  
  METHODS
  This was a prospective pilot study. Seven infertile, CC-resistant, PCOS patients with dyslipidemia were enrolled in this study. The participants received bezafibrate at 400 mg/day from day 1 of menses and CC at 100 mg/day from day 5 of menses simultaneously until one follicle measuring at least 18 mm in diameter was found by transvaginal ultrasound. The main outcome was ovulation rate.
  
  
  RESULTS
  Five of 7 patients successfully ovulated. The mean number of days of menses until the follicle reached 18 mm in diameter was 16 ± 3 (range 13-20). Monofollicular development was observed in all patients that ovulated. One woman became pregnant and delivered a healthy baby.
  
  
  CONCLUSIONS
  Bezafibrate may be effective for ovulation induction in CC-resistant PCOS patients with dyslipidemia.
authors.affiliation: Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan.
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Hara
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Amita
authors.forename: Hideki
authors.initials: H
authors.lastname: Igarashi
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Kurachi
mesh_terms: D000328:Adult; D001629:Bezafibrate / Q000627:therapeutic use*; D002996:Clomiphene / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy*; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007247:Infertility, Female / Q000188:drug therapy* / Q000209:etiology; D010062:Ovulation Induction / Q000379:methods*; D010865:Pilot Projects; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies
chemical_list: D005300:Fertility Agents, Female; D000960:Hypolipidemic Agents; D002996:Clomiphene; D001629:Bezafibrate